C

CG Oncology, Inc. (CGON)

NMS – Real vaqt narxi. Valyuta: USD

72.07

+2.75 (3.97%)

Yopilishda: May 12, 2026, 4:00 PM EDT

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Barcha huquqlar himoyalangan.

Foydalanish shartlari

C

CG Oncology, Inc. (CGON)

NMS – Real vaqt narxi. Valyuta: USD

72.07

+2.75 (3.97%)

Yopilishda: May 12, 2026, 4:00 PM EDT

12.05.2026

CG Oncology, Inc. (CGON) Presents at Bank of America Global Healthcare Conference 2026 Transcript

11.05.2026

CG Oncology's Presence at American Urological Association (AUA) Annual Meeting Underscores its Strong Commitment to NMIBC

-First results from CORE-008 Cohort CX Phase 2 Trial evaluating intravesical combination therapy in High-Risk BCG-Exposed and BCG-Unresponsive patients to be presented-

11.05.2026

CG Oncology Analysts Boost Their Forecasts Following Q1 Earnings

CG Oncology (NASDAQ:CGON) reported mixed results for the first quarter on Friday.

08.05.2026

CG Oncology, Inc. (CGON) Reports Q1 Loss, Tops Revenue Estimates

CG Oncology, Inc. (CGON) came out with a quarterly loss of $0.71 per share versus the Zacks Consensus Estimate of a loss of $0.58. This compares to a loss of $0.45 per share a year ago.

08.05.2026

CG Oncology Reports First Quarter 2026 Financial Results and Provides Business Updates

DALLAS, May 08, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today reported financial results for the first quarter ended March 31, 2026, and provided business updates.

05.05.2026

Wall Street Analysts Think CG Oncology, Inc. (CGON) Could Surge 29.78%: Read This Before Placing a Bet

The consensus price target hints at a 29.8% upside potential for CG Oncology, Inc. (CGON). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

05.05.2026

CG Oncology to Present at Upcoming Investor Conferences in May

DALLAS, May 05, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced that Arthur Kuan, Chairman & Chief Executive Officer, and Ambaw Bellete, President & Chief Operating Officer, will participate in fireside chat presentations at the Bank of America Health Care Conference and the RBC Capital Markets Global Healthcare Conference this month. The details of the upcoming events are as follows: Bank of America Health Care Conference 2026 Date: Tuesday, May 12, 2026Presentation Time: 10:40 AM – 11:10 AM PTLocation: Las Vegas, NV RBC Capital Markets Global Healthcare Conference Date: Wednesday, May 20, 2026Presentation Time: 2:35 PM – 3:00 PM ETLocation: New York, NY Interested parties may access the live audio webcast for the conferences from the Investor Relations section of the company's website at www.cgoncology.com.

Videolar

No Data

There is no data to display

Press-relizlar

11.05.2026

CG Oncology's Presence at American Urological Association (AUA) Annual Meeting Underscores its Strong Commitment to NMIBC

-First results from CORE-008 Cohort CX Phase 2 Trial evaluating intravesical combination therapy in High-Risk BCG-Exposed and BCG-Unresponsive patients to be presented-

08.05.2026

CG Oncology Reports First Quarter 2026 Financial Results and Provides Business Updates

DALLAS, May 08, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today reported financial results for the first quarter ended March 31, 2026, and provided business updates.

27.02.2026

CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates

IRVINE, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today reported financial results for the fourth quarter and year ended December 31, 2025, and provided business updates.

09.01.2026

CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC

- PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy for intermediate-risk NMIBC now expected in 1H 2026, nearly one year ahead of schedule

Search stocks

CG Oncology, Inc. (CGON)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

CG Oncology, Inc. (CGON)

CG Oncology, Inc. (CGON) Presents at Bank of America Global Healthcare Conference 2026 Transcript

CG Oncology's Presence at American Urological Association (AUA) Annual Meeting Underscores its Strong Commitment to NMIBC

CG Oncology Analysts Boost Their Forecasts Following Q1 Earnings

CG Oncology, Inc. (CGON) Reports Q1 Loss, Tops Revenue Estimates

CG Oncology Reports First Quarter 2026 Financial Results and Provides Business Updates

Wall Street Analysts Think CG Oncology, Inc. (CGON) Could Surge 29.78%: Read This Before Placing a Bet

CG Oncology to Present at Upcoming Investor Conferences in May

Videolar

No Data

Press-relizlar

CG Oncology's Presence at American Urological Association (AUA) Annual Meeting Underscores its Strong Commitment to NMIBC

CG Oncology Reports First Quarter 2026 Financial Results and Provides Business Updates

CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates

CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC